Nigerian pharmacists say 70% local medicine production target is unrealistic
By the AFREEQUE newsroom, based on Punch
According to pharmacists and manufacturers, Nigeria risks failing to produce 70% of its essential medicines locally by 2030 because of unfavourable conditions. They cite high energy and production costs, a lack of financing and foreign exchange difficulties, according to Punch.
Pharmacists and industrialists in Nigeria’s pharmaceutical sector believe the country risks failing to meet its target of producing 70% of its essential medicines locally by 2030. They say this ambition depends on structural reforms and a favourable economic environment, according to statements collected by Punch Healthwise.
Ayuba Tanko, president of the Pharmaceutical Society of Nigeria, considers the timetable particularly difficult to meet at the current pace. He believes Nigeria has a large market, qualified professionals and companies capable of developing domestic production, but that industrial conditions remain inadequate. Manufacturers are calling in particular for a stable energy supply, access to affordable raw materials and better financing opportunities.
High production costs, difficulties accessing foreign currency and financial constraints are also holding back investment. Despite programmes launched by the federal government to support the local pharmaceutical industry, these obstacles continue to limit the capacity of domestic companies.
In February 2026, Muhammadu Sanusi II, Emir of Kano, said that 70% of medicines consumed in Nigeria were imported. He also estimated that India accounted for 80% of these imports, during a conference organised in Lagos by the Association of Industrial Pharmacists of Nigeria. The World Health Organization (WHO) has also set a target for Nigeria to produce 70% of its medicines domestically by 2030.
Difficulties in local production come amid concerns about the quality of medicines marketed in Nigeria. On 18 November, Nigerian lawmakers summoned the National Agency for Food and Drug Administration and Control (NAFDAC) over counterfeit medicines. The lawmakers' summons to NAFDAC highlights another dimension of the country’s pharmaceutical safety challenges.






